Navidea Biopharmaceuticals (NAVB) & Its Rivals Head to Head Analysis

Navidea Biopharmaceuticals (NYSE: NAVB) is one of 30 publicly-traded companies in the “Diagnostic substances” industry, but how does it compare to its competitors? We will compare Navidea Biopharmaceuticals to related businesses based on the strength of its analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.


This table compares Navidea Biopharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Navidea Biopharmaceuticals -1,385.19% -5,162.95% -211.04%
Navidea Biopharmaceuticals Competitors -971.44% -311.53% -44.15%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Navidea Biopharmaceuticals and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Navidea Biopharmaceuticals 0 0 0 0 N/A
Navidea Biopharmaceuticals Competitors 340 864 1083 100 2.40

As a group, “Diagnostic substances” companies have a potential upside of 7.54%. Given Navidea Biopharmaceuticals’ competitors higher probable upside, analysts plainly believe Navidea Biopharmaceuticals has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Navidea Biopharmaceuticals and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Navidea Biopharmaceuticals $660,000.00 -$10.95 million -3.62
Navidea Biopharmaceuticals Competitors $346.45 million -$16.01 million 95.06

Navidea Biopharmaceuticals’ competitors have higher revenue, but lower earnings than Navidea Biopharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

5.9% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 53.0% of shares of all “Diagnostic substances” companies are held by institutional investors. 0.5% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 8.5% of shares of all “Diagnostic substances” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Navidea Biopharmaceuticals has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals’ competitors have a beta of 1.61, suggesting that their average stock price is 61% more volatile than the S&P 500.


Navidea Biopharmaceuticals competitors beat Navidea Biopharmaceuticals on 8 of the 10 factors compared.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. In addition, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. Further, the company is developing diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a preclinical therapeutic research collaboration with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.